FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2557742543> ?p ?o ?g. }

• W2557742543 abstract "Abstract Background Cytotoxic agents are a well-established risk factor for therapy related myeloid neoplasms (t-MN). The incidence of t-MN in patients (pts) with autoimmune diseases (AID) treated with cytotoxic and immuno-modulatory agents are not well described in the literature. Most case series assess an MDS/AML population and co-occurrence with an AID. To our knowledge, there exists no large case-control studies evaluating a primary AID population that developed therapy-related MDS or AML, and the relationship to detailed therapeutic intervention for AID. Our study queries the association of cytotoxic and immune-modulating agents to treat AID as risk factor for developing MDS or AML. Methods Between 2004-2014, 23,671 pts with an ICD-9 coded AID were seen at Mayo Clinic Arizona; 148 pts from this population had a concomitant coded diagnosis of MDS/AML. In an IRB approved, retrospective chart review we confirmed 61 cases meeting strict inclusion criteria. We performed a case-control match from the same primary AID population for age, gender, and autoimmune specific diagnosis at a 2:1 ratio. AML/MDS cases were compared to controls by use of chi-square test for frequency data. Odds ratios with 95% confidence interval were constructed using conditional logistic regression. Case incidence was compared to SEER data for the general population Results Of 61 cases 33 were MDS, 20 de-novo AML, and 8 MDS transformed to AML. Psoriasis 16 (26.2%) and rheumatoid arthritis 14 (23.0%) were the most common autoimmune diagnoses, followed by systemic lupus 11 (18%), Crohn's disease 7 (11.5%), and ulcerative colitis 5 (8.2%). 39 out of 61 cases (63.9%) received either a cytotoxic or immune modulating agent for AID, compared to 64/122 (52.5%) in the control group; p=0.140. 7/61 cases (11.5%) received both a cytotoxic and immune modulating agent as compared to 16/122 (13.1%) in controls; p=0.753. Overall, the case population received more agents than controls. No cytotoxic or immune-modulating treatment was documented in 16% of cases and 36% controls. Exposures to cytotoxic and immune-modulating agents were similar in both case and control cohorts. Exposure time was not statistically significant. Azathioprine was the only statistically significant agent exposure observed more often in the case cohort than control. Per SEER data, over a 10-year period in a general age-matched population that is comparable to our AID population cohort, we would expect 54 MDS and 35 AML cases. Table 1. Exposures and Timeline Cases (n=61) Controls (n=122) P value * Number of Systemic Agents, Total None 1 2 3 4+ - 10 (16.4%) 26 (42.6%) 12 (19.7%) 7 (11.5%) 6 (9.8%) - 44 (36.1%) 32 (26.2%) 31 (25.4%) 9 (7.4%) 6 (4.9%) 0.020 Exposure to Cytotoxic agent < 1 year 2-5 years 6-10 years 11 years or more Unknown (n=26) 7 (26.9%) 6 (23.1%) 5 (19.2%) 3 (11.5%) 5 (19.2%) (n=43) 5 (11.6%) 8 (18.6%) 6 (13.9%) 12 (27.9%) 12 (27.9%) 0.276 Exposure to Immune modulating agent < 1 year 2-5 years 6-10 years 11 years or more Unknown (n=20) 6 (30%) 6 (30%) 3 (15%) 1 (5%) 4 (20%) (n=37) 6 (16.2%) 10 (27.0%) 5 (13.5%) 3 (8.1%) 13 (35.1%) 0.661 Table 2. Treatments and Odds Ratio Odds Ratio 95% CI for OR P value * Cytotoxic OVERALLAzathioprine Cyclophosphamide Methotrexate Mitoxantrone 6-MP Mycophenolate 1.39 4.16 1.28 0.74 2.73 1.00 1.21 0.72, 2.67 1.29, 13.44 0.24, 6.89 0.29, 1.88 0.23, 33.0 0.23, 4.35 0.28, 5.21 0.322 0.017 0.773 0.528 0.429 0.999 0.803 Immune modulating agent OVERALLAnti-TNF Leflunomide Plaquenil 1.19 0.73 2.00 2.73 0.52, 2.73 0.24, 2.24 0.40, 9.91 0.80, 8.33 0.672 0.585 0.396 0.077 Discussion Treatment of AID does not seem to increase the incidence of MDS or AML. Furthermore, the incidence of myeloid neoplasm occurring in association with treatment of AID is not higher than expected in the general SEER population. However, the case cohort was exposed to more agents overall and more likely to have exposure to azathioprine than controls. Limitations of our study are associated with its retrospective nature, possible associated underrepresentation of t-MN, and autoimmune population profile. Nevertheless, this is the largest case study with detailed drug exposures with timelines for pts with AID, contributing to a better understanding regarding possible risk of developing MDS/AML in pts treated for AID. Confirmation of the same study at Mayo Clinic Rochester and Florida are ongoing. Disclosures Al-Kali: Novartis: Research Funding." @default.
• W2557742543 created "2016-12-08" @default.
• W2557742543 creator A5001494864 @default.
• W2557742543 creator A5008422091 @default.
• W2557742543 creator A5018041025 @default.
• W2557742543 creator A5023290487 @default.
• W2557742543 creator A5030463388 @default.
• W2557742543 creator A5031799824 @default.
• W2557742543 creator A5035051206 @default.
• W2557742543 creator A5038693643 @default.
• W2557742543 creator A5073183082 @default.
• W2557742543 creator A5082365813 @default.
• W2557742543 creator A5085167360 @default.
• W2557742543 creator A5090009905 @default.
• W2557742543 date "2015-12-03" @default.
• W2557742543 modified "2023-09-28" @default.
• W2557742543 title "Myelodysplastic Syndromes and Acute Myelogenous Leukemia Resulting from Therapy for Autoimmune Disease, a Case-Control Cohort Study" @default.
• W2557742543 doi "https://doi.org/10.1182/blood.v126.23.5636.5636" @default.
• W2557742543 hasPublicationYear "2015" @default.
• W2557742543 type Work @default.
• W2557742543 sameAs 2557742543 @default.
• W2557742543 citedByCount "0" @default.
• W2557742543 crossrefType "journal-article" @default.
• W2557742543 hasAuthorship W2557742543A5001494864 @default.
• W2557742543 hasAuthorship W2557742543A5008422091 @default.
• W2557742543 hasAuthorship W2557742543A5018041025 @default.
• W2557742543 hasAuthorship W2557742543A5023290487 @default.
• W2557742543 hasAuthorship W2557742543A5030463388 @default.
• W2557742543 hasAuthorship W2557742543A5031799824 @default.
• W2557742543 hasAuthorship W2557742543A5035051206 @default.
• W2557742543 hasAuthorship W2557742543A5038693643 @default.
• W2557742543 hasAuthorship W2557742543A5073183082 @default.
• W2557742543 hasAuthorship W2557742543A5082365813 @default.
• W2557742543 hasAuthorship W2557742543A5085167360 @default.
• W2557742543 hasAuthorship W2557742543A5090009905 @default.
• W2557742543 hasConcept C120665830 @default.
• W2557742543 hasConcept C121332964 @default.
• W2557742543 hasConcept C126322002 @default.
• W2557742543 hasConcept C143998085 @default.
• W2557742543 hasConcept C156957248 @default.
• W2557742543 hasConcept C203014093 @default.
• W2557742543 hasConcept C2780007613 @default.
• W2557742543 hasConcept C2780817109 @default.
• W2557742543 hasConcept C2908647359 @default.
• W2557742543 hasConcept C61511704 @default.
• W2557742543 hasConcept C71924100 @default.
• W2557742543 hasConcept C99454951 @default.
• W2557742543 hasConceptScore W2557742543C120665830 @default.
• W2557742543 hasConceptScore W2557742543C121332964 @default.
• W2557742543 hasConceptScore W2557742543C126322002 @default.
• W2557742543 hasConceptScore W2557742543C143998085 @default.
• W2557742543 hasConceptScore W2557742543C156957248 @default.
• W2557742543 hasConceptScore W2557742543C203014093 @default.
• W2557742543 hasConceptScore W2557742543C2780007613 @default.
• W2557742543 hasConceptScore W2557742543C2780817109 @default.
• W2557742543 hasConceptScore W2557742543C2908647359 @default.
• W2557742543 hasConceptScore W2557742543C61511704 @default.
• W2557742543 hasConceptScore W2557742543C71924100 @default.
• W2557742543 hasConceptScore W2557742543C99454951 @default.
• W2557742543 hasLocation W25577425431 @default.
• W2557742543 hasOpenAccess W2557742543 @default.
• W2557742543 hasPrimaryLocation W25577425431 @default.
• W2557742543 hasRelatedWork W185403751 @default.
• W2557742543 hasRelatedWork W1874606231 @default.
• W2557742543 hasRelatedWork W1987178328 @default.
• W2557742543 hasRelatedWork W2024565997 @default.
• W2557742543 hasRelatedWork W2049698649 @default.
• W2557742543 hasRelatedWork W2077702295 @default.
• W2557742543 hasRelatedWork W2083357419 @default.
• W2557742543 hasRelatedWork W2339181466 @default.
• W2557742543 hasRelatedWork W2580838441 @default.
• W2557742543 hasRelatedWork W2585794098 @default.
• W2557742543 hasRelatedWork W2596557772 @default.
• W2557742543 hasRelatedWork W2606235304 @default.
• W2557742543 hasRelatedWork W2885486546 @default.
• W2557742543 hasRelatedWork W2893157368 @default.
• W2557742543 hasRelatedWork W2901274974 @default.
• W2557742543 hasRelatedWork W2904623921 @default.
• W2557742543 hasRelatedWork W2912545933 @default.
• W2557742543 hasRelatedWork W2915259473 @default.
• W2557742543 hasRelatedWork W3095024820 @default.
• W2557742543 hasRelatedWork W3160658638 @default.
• W2557742543 isParatext "false" @default.
• W2557742543 isRetracted "false" @default.
• W2557742543 magId "2557742543" @default.
• W2557742543 workType "article" @default.